FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES (Q2035463)
Jump to navigation
Jump to search
Project Q2035463 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES |
Project Q2035463 in Italy |
Statements
186,460.21 Euro
0 references
372,920.43 Euro
0 references
50.0 percent
0 references
14 February 2017
0 references
13 October 2019
0 references
EVVIVAX S.R.L.
0 references
ISTITUTO SUPERIORE DI SANITA'
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
I VACCINI GENETICI HANNO MOLTEPLICI VANTAGGI POTENZIALI, TRA CUI IL TARGETING SPECIFICO, L'USO DI GENI MULTIPLI PER MIGLIORARE L'IMMUNITà , LA VELOCITà DI SINTESI E LA RIDUZIONE DEL RISCHIO RISPETTO AI VACCINI CONVENZIONALI. EVVIVAX Ê UNA NUOVA AZIENDA CH (Italian)
0 references
GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH (English)
0 references
LES VACCINS GÉNÉTIQUES PRÉSENTENT DE MULTIPLES AVANTAGES POTENTIELS, Y COMPRIS UN CIBLAGE SPÉCIFIQUE, L’UTILISATION DE GÈNES MULTIPLES POUR AMÉLIORER L’IMMUNITÉ, LA VITESSE DE SYNTHÈSE ET LA RÉDUCTION DES RISQUES PAR RAPPORT AUX VACCINS CONVENTIONNELS. EVVIVAX Ê UNE NOUVELLE ENTREPRISE QUI (French)
16 December 2021
0 references
GENETISCHE VACCINS HEBBEN MEERDERE POTENTIËLE VOORDELEN, WAARONDER SPECIFIEKE TARGETING, HET GEBRUIK VAN MEERDERE GENEN OM DE IMMUNITEIT, DE SYNTHESESNELHEID EN DE RISICOVERMINDERING TE VERBETEREN IN VERGELIJKING MET CONVENTIONELE VACCINS. EVVIVAX Ê EEN NIEUW BEDRIJF DAT (Dutch)
23 December 2021
0 references
Identifiers
F89J18000160007
0 references